Replies to post #12462 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

Dumb idea #2

GTC's principal asset is its novel protein production platform,,its principal problem is the encumberances (sp?)throw up by the regulators.. Should the company be searching for a protein that has uses other than medical,,eg. in industry, chemical engineering, nanotechnology, etc which would not require the insane delays created by the FDA????

[DewDiligence]

Re: rFVIIa use by DoD

>Dumb idea number one: Since FVII has possible military implications in treating major trauma, and is in short supply, would there be any be possibility GTC might get a contract from the ONR or Army to study and develop an alternate supply for the military. They are not FDA bound, and have lots of money...<

NovoSeven is not in short supply. (Why did you think it was?)

The problem with NovoSeven is its high price, which limits demand for prophylactic use and renders the drug unaffordable for any use in many Third World countries.

Inasmuch as: a) the US DoD uses NovoSeven as a treatment rather than a prophylaxis; b) DoD has “lots of money” and c) NovoSeven probably accounts for less than 0.001% of DoD’s budget, I doubt that a cheaper version of rFVIIa ranks high on DoD’s want list.